Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis

Malignancies in HIV/AIDS

(2014) Paul G. Rubinstein et al.   AIDS

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Anti-CD20 monoclonal antibodies: Beyond B-cells

(2013) Irit Avivi et al.   BLOOD REVIEWS

Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study

(2013) Emanuele Zucca et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

(2013) Ruth Pettengell et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

(2012) C. Muller et al.   BLOOD

Rituximab-induced direct inhibition of T-cell activation

(2012) Dina Stroopinsky et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

(2012) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of Older Patients with Mantle-Cell Lymphoma

(2012) H.C. Kluin-Nelemans et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis

(2011) M. Pirani et al.   ANNALS OF ONCOLOGY

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma

(2011) R. Griffiths et al.   BLOOD

Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: An Updated Systematic Review and Meta-analysis of Randomized Trials

(2011) Liat Vidal et al.   JNCI-Journal of the National Cancer Institute

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

(2011) Michael Pfreundschuh et al.   LANCET ONCOLOGY

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

(2010) B. Coiffier et al.   BLOOD

Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non-Hodgkin's Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study

(2010) Marinus H.J. van Oers et al.   JOURNAL OF CLINICAL ONCOLOGY

Second Malignancy Risks After Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: Differences by Lymphoma Subtype

(2010) Lindsay M. Morton et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98

(2010) Giovanni Martinelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

(2010) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

(2010) Gilles Salles et al.   LANCET

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

(2008) Michael Pfreundschuh et al.   LANCET ONCOLOGY

Cancer Immunology

(2008) Olivera J. Finn   NEW ENGLAND JOURNAL OF MEDICINE